Key clinical message:
Myasthenia gravis is a rare burdensome condition that severely impacts
patients’ quality of life—often exacerbated by side effects from
long-term immunosuppressive therapy. Although effective therapies exist,
more real-world evidence is needed to guide decision-making in
refractory cases where treatment discontinuation is considered and can
significantly worsen a patient’s condition.